New York
Einstein-Montefiore Institute for Clinical and Translational Research
Bronx, New York
Principal Investigator
Harry Shamoon, M.D., Albert Einstein College of Medicine
Pediatric clinical research is a vital component of the enterprise sponsored by the Einstein-Montefiore Institute for Clinical and Translational Research.
The Einstein-Montefiore Institute for Clinical and Translational Research (ICTR) is founded on successful interdependent programs comprising pediatric and adult patient research facilities, core laboratories, and expanded clinical research training programs, including a Ph.D. in clinical investigation. Jointly supported by the Albert Einstein College of Medicine and Montefiore Medical Center, ICTR encourages the development of new methods and approaches to bidirectional clinical and translational research. One focus will be on the improvement of education, training and mentoring to aid new investigators in navigating the increasingly complex research system, while taking advantage of newly designed and improved biomedical research informatics tools. ICTR actively engages the ethnically diverse communities of the Bronx, made up of 1.4 million people, collaborating with regional and affiliated institutions to expand research and training opportunities throughout the Bronx community. ICTR builds upon existing clinical research programs, such as the Hispanic Community Health Study; on interdisciplinary centers in diabetes, cancer, liver, health disparities, neuroscience, transplantation and HIV/AIDS; and on an expanding base of translational research faculty in genetics, systems biology and stem cell research, many of whom are housed in a new state-of-the-art facility. ICTR will enhance community collaboration and participation in its research, as well as expand and develop partnerships with community organizations in the Bronx. During the past two years, the Clinical and Translational Science Award development process has involved a broad range of faculty from numerous disciplines (including medicine, dentistry, nursing, epidemiology, social work and biomedical sciences) through these transformative partnerships.
Irving Institute for Clinical and Translational Research
New York, New York
Principal Investigator
Henry Ginsberg, M.D., Columbia University
The CTSA grant supports clinical and translational research at Columbia University Medical Center, such as Dr. Howard Kaufman's research on tumor immunology and cancer vaccines. (Columbia University Medical Center Photo)
Columbia University Medical Center's (CUMC) CTSA program will transform the culture of clinical and translational research so that CUMC can develop and retain an outstanding cadre of senior faculty to lead the next generation of clinical and translational investigators. With enhanced support from the CUMC-Herbert Irving Endowment, which will increase from its present level of $15 million to $25 million, CUMC will accomplish this goal by creating the Irving Institute for Clinical and Translational Research (IICTR). IICTR will be the academic and intellectual home for the next generation of clinical and translational investigators. The senior faculty will provide leadership and stature for IICTR, and serve as mentors for both the junior faculty and IICTR trainees. The junior faculty, called Irving Fellows, will work with senior faculty to develop novel approaches to advancing multi- and interdisciplinary clinical and translational research. The Irving Fellows will be role models for the way multi- and interdisciplinary research should be conducted at CUMC. The resources provided by IICTR will include outstanding support and research in biomedical informatics, biostatistical and clinical trial design, bioethics, regulatory issues, patient-oriented research, and core laboratory resources. The Irving Fellows will be supported by CUMC and the CTSA, as will pilot and collaborative research grants awarded annually by IICTR. CUMC has invested in the development of new space for IICTR, including space for pediatric inpatient/outpatient research and the Center for Clinically Oriented Research Education, which will be a home for trainees and faculty. CUMC will also develop a new off-campus research center to support community-based clinical and translational research, and education. As part of the CTSA program, CUMC has created an integrated educational program that includes a new multidisciplinary, patient-oriented research master's degree, a novel K12 scholars mentored research program in muti- and interdisciplinary research, and a pioneering multidisciplinary, patient-oriented research Ph.D. program. The goal of IICTR and the CTSA program is to enable more direct utilization of research advances to benefit patients and the community.
Conduits, The Institutes for Translational Sciences at the Mount Sinai School of Medicine
New York, New York
Principal Investigator
Barbara T. Murphy, M.D., Mount Sinai School of Medicine
Hugh Sampson, M.D. (left), dean for translational biomedical sciences and the Kurt Hirschhorn Professor of Pediatrics at Mount Sinai School of Medicine, discusses the results of an experiment investigating the cellular mechanisms of peanut allergy. Joining him are student Steven Woo (center) and Wayne Shreffler, M.D., Ph.D. (right), assistant professor of pediatrics at Mount Sinai School of Medicine. (Matthew Septimus Photo)
The goal of Conduits, the Institutes for Translational Sciences at the Mount Sinai School of Medicine is to establish a research paradigm that will: 1) facilitate bench-to-bedside translation of cutting-edge research, 2) create an academic home for clinical and translational investigators, and 3) supply the governance and resources needed to allow clinical investigators to benefit from Mount Sinai's Translational Research Institutes and potential collaborators.
To accomplish this, Conduits will redesign its research infrastructure to integrate research functions across departments, enhance and promote interactions between basic scientists and clinical investigators, and streamline administrative procedures for new clinical trials and dissemination of results. It will establish a Translational Discoveries Program to provide consultation, oversight and facilities for clinical and translational research. Conduits also will engage the community and its affiliates to translate health benefits to the public. And it will develop methodologies to improve trial design and reduce participant burden.
To recruit and retain clinical and translational researchers, Conduits will train and support new investigators in a multidisciplinary, doctoral degree-granting program in clinical and translational research. It also will develop a recruitment program and enhance career development. An innovative Experimental Therapeutics & Technologies Program will identify and develop novel clinical and translational research projects and connect basic and clinical researchers, caregivers and laboratories through an integrated network of information.
Conduits will create an effective, efficient and centralized research administrative structure. It will foster and reward interdisciplinary collaborations, educate and retain new clinical and translational investigators, and enable translation of basic scientific discoveries into clinical practice. Conduits also will deliver to its diverse community new therapies and an improved standard of care.
NYU/HHC Clinical and Translational Science Institute
New York, New York
Principal Investigators
Bruce Neil Cronstein, M.D., New York University
Judith S. Hochman, M.D., New York University
Gbenga Ogedegbe, M.D., M.P.H., M.S., as seen with his patient, is an associate professor of medicine in the Division of General Internal Medicine and director of the Center for Healthful Behavior Change at the NYU School of Medicine. Dr. Ogedegbe's research is focused on the translation and dissemination of evidence-based behavioral interventions targeted at cardiovascular risk reduction in minority and underserved populations in community settings and primary care practices. (Mike Weymouth Photo)
To transform the way research is carried out at New York University (NYU) and enhance the quality and productivity of the research effort, NYU and the New York City Health and Hospitals Corporation (HHC) has established a Clinical and Translational Science Institute (CTSI). CTSI aims to increase collaboration among clinical, translational and basic scientists across NYU to better determine the relevance and applicability of scientific advances to clinical problems. It also strives to provide leadership, infrastructure and resources to support novel science and the rapid, efficient and safe application of scientific discoveries to the community. A third aim is to support education, training and development of researchers who can conduct the investigations necessary to bring scientific advances to the public. Finally, CTSI works to enhance the ties between NYU researchers and the community in order to more rapidly identify health problems, investigate their scientific basis, apply the knowledge gained, promote use of new developments and evidence-based medicine by the community, and reduce health care disparities.
CTSI links NYU and the HHC in a new venture designed to bring their resources to bear on the health problems facing New York and the nation in the 21st century. Combining strengths and synergies in research, patient care and community outreach, it provides a new and innovative engine for translation of medical advances from the laboratory to the patient and from the patient to the community.
Rockefeller University Center for Clinical and Translational Science
New York, New York
Principal Investigator
Barry Coller, M.D., Rockefeller University
The Rockefeller University Hospital, originally a General Clinical Research Center awardee since 1963, has been the continuous home for clinical and translational science at Rockefeller since 1910. It has been the site of numerous landmark scientific and clinical contributions, and many of its trainees have gone on to become academic leaders. With the new resources available under a Clinical and Translational Science Award (CTSA), a core faculty of distinguished investigators, whose research spans the basic-translational spectrum and encompasses a broad range of scientific and medical disciplines, integrates and expands Rockefeller University's scientific and educational programs in the Rockefeller University Center for Clinical and Translational Science. The new center transforms clinical and translational research by encouraging new studies, enhancing and centralizing the support structures required to conduct studies with scientific rigor, and ensuring an absolute commitment to the protection of human subjects and participant safety. The key elements in the transformation are: 1) a new governance structure reflecting the NIH cooperative agreement (U54) assistance mechanism; 2) creation of a new K12 Clinical Research Scholars Program offering master's and Ph.D.-level degrees to complement the current Clinical Scholars Program; 3) infrastructure enhancements to facilitate the development and conduct of clinical protocols under the principle of good clinical practice, including biomedical informatics, biostatistics, bionutrition, research nursing, research pharmacy, participant recruitment and community engagement, and regulatory support and oversight from the clinical research (research subject advocate) support office; and 4) development of innovative and novel core methodologies related to dendritic cell therapy; vaccine development for HIV, hepatitis C and malignancies; genetics/genomics; assessing the immune response; and metabolic phenotyping. The center continues Rockefeller's tradition of focusing on the interface between scientific discovery; human pathophysiology; and novel diagnostic, preventive and therapeutic strategies. It partners with industry, when mutually beneficial, to achieve these goals. The center is an active member of the national CTSA consortium, offering the consortium novel ideas and tools for conducting and evaluating clinical and translational research. It eagerly adopts the best practices identified by the consortium and adheres to the standards set by the consortium.
University of Rochester Clinical and Translational Science Institute
Rochester, New York
Principal Investigator
Thomas Pearson, M.D., M.P.H., Ph.D., University of Rochester Medical Center
The University of Rochester Clinical and Translational Science Institute provides an optimal setting for medical investigators to conduct safe, controlled, inpatient and outpatient studies. Richard T. Moxley III, M.D., professor of neurology and pediatrics at the University of Rochester School of Medicine and Dentistry, visits with a patient in the Clinical Research Center. (Ken Huth Photo)
The University of Rochester Clinical and Translational Science Institute (CTSI), funded through the Clinical and Translational Science Award program, serves as the academic home for clinical and translational science at the university. The CTSI acts as a hub, integrating clinical and translational science programs and related academic departments with four affiliated URMC research centers, namely the Center for Human Experimental Therapeutics, the Clinical Research Center, the Center for Research Implementation and Translation, and the Center for Community Health.
Since its inception in 2006, the CTSI has achieved many noteworthy accomplishments: 1) Created and supports the UNYTE Translational Research Network made up of 18 biomedical research institutions in and near Upstate New York. Among other things, UNYTE implemented a model for collaborative Institutional Review Board review of multisite protocols to accelerate the approval time for research studies conducted within the network. 2) Established a Research Navigator program to facilitate, accelerate and improve collaboration in clinical and translational research within the URMC, across the UNYTE network, and throughout the CTSA Consortium. 3) Initiated and supports the Greater Rochester Practice-Based Research Network, which consists of 85 pediatric, internal medicine and family medicine practices that serve 30 percent of the adult and 80 percent of the pediatric population in the region. 4) Created an innovative new Ph.D. program to prepare individuals for academic and clinical careers related to the translation of basic biomedical research into clinical strategies to improve health.
Clinical and Translational Science Center
New York, New York
Principal Investigator
Julianne L. Imperato-McGinley, M.D., Weill Cornell Medical College
Dr. Nasser Altorki, director of the Division of Thoracic Surgery at New York-Presbyterian Hospital/Weill Cornell Medical Center, confers with a colleague about a CT scan of a patient's chest. (Weill Cornell Medical College Photo)
The Clinical and Translational Science Center (CTSC) — comprising public/private institutions on the Upper East Side of Manhattan — is a unique and diverse biomedical complex, providing investigators with state-of-the-art resources for conducting clinical and translational research.
Weill Cornell Medical College of Cornell University, the lead institution, serves as a conduit through which technological resources and educational programs are efficiently shared and managed. Neighboring institutions contribute significantly to the CTSC. Hospital for Special Surgery, a leader in investigating musculoskeletal and autoimmune diseases, is one of two medical institutions designated by NIH as a Core Center for Skeletal Integrity. Memorial Sloan-Kettering Cancer Center is a cancer center where state-of-the-art basic science research flourishes side-by-side with clinical investigation and treatment at Memorial Hospital. Cornell University Cooperative Extension, NYC, engaged in research addressing the needs of a changing New York for over 50 years, will be the linchpin for community outreach. Hunter College Gene Center's Research Center for Minority Institutions recruits and nurtures minority talent and has established an effective electronic network with minority scientists nationwide. Hunter College School of Nursing, training nurses from a diverse urban population, will participate in community outreach and education in underserved areas.
Social Media Links